Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)

CLIENT'S NEWS

acticor
admin

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Paris, France, June 29, 2022 – 6:00 p.m. CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specialized in the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces that the European Patent Office (EPO) has granted a new patent that strengthens Acticor Biotech’s patent portfolio. It provides protection for the use of glenzocimab in thrombotic diseases in Europe until 2036.

Read More »

Latest Insights

Neurofenix secures $7million to fuel expansion

Digital neuro-rehabilitation platform Neurofenix, which is helping to revolutionise remote rehabilitation for stroke patients, has secured $7million to help fuel its expansion and fund clinical trials in the United States.

Subtle Medical Announces Partnership Expansion With Incepto

Subtle Medical, a healthcare technology company improving the quality and efficiency of medical imaging, announced they are expanding their partnership with Incepto, a leading platform of artificial intelligence solutions for radiology professionals in Europe, by offering their AI applications, SubtleMR and SubtlePET on Incepto’s platform.

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.